Bill
S 6422
Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy
2025 Regular Session
Introduced by Jeremy Cooney and 1 co-sponsor
Bill S 6422 mandates clearer prescription labels for hormone-related medications, enhancing patient understanding and safety, improving adherence, and supporting healthcare providers.
REFERRED TO HIGHER EDUCATION